Bifidobacterium longum subsp. infantis / Postbiotics Powder

Bifidobacterium longum subsp. infantis

Breastmilk is the primary source of nutrition in early infancy, and it meets all the nutritional needs of infants up to six months after birth. Breastmilk also contains many bioactive substances that can regulate intestinal flora, promote the development of the immune system and strengthen the intestinal barrier. Human milk oligosaccharides (HMOs), one of the active substances in breast milk, cannot be directly digested and absorbed by infants, but can act as a prebiotic to stimulate the establishment and evolution of intestinal flora. Bifidobacterium longum subsp. infantis, the dominant microorganism in the gut of breastfed infants, possesses almost all the gene clusters required to metabolise the major HMOs, and its interactions with HMOs play a key role in early infant gut health.

National laws and regulations of Postbiotics

European Union

Although the European Union has not enacted specific regulations for postbiotics, some have been marketed or regulated as immunostimulants. Furthermore, to ensure effective regulation of microorganisms used in food and feed, the EU has proposed the Qualified Presumption of Safety (QPS) management concept and established a regularly updated QPS list of biological agents, which could provide an opportunity for the safety assessment of microorganisms used in postbiotic production.

United States

The FDA does not have specific evaluation or inspection procedures for postbiotics; however, since postbiotics can be developed under various regulatory categories, the FDA may select particular regulatory category standards based on the anticipated use, safety, and efficacy of the postbiotics.

China

China has established a group standard titled "Probiotics Products Lactobacillus Postbiotics."

Applications

Food

Dairy

Personal Care

Environmental Protection

Daily Chemicals

Pet

Preservatives

Products List